Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Benefit From OTC Switches Supported In Study Of PPIs' Outpatient Impact

Executive Summary

Proton pump inhibitor OTC switches since 2003 had a profound and sustained impact on outpatient health care visits – illustrating the potential for other switches to benefit US health care, a recent study suggests.


Related Content

Private Label Competition For Zegerid OTC Sets Sail With Perrigo Launch
Merck Silence On OTC Singulair Speaks Volumes On Switch Outlook
CAGR For OTC Switch Forecast At 5%, But Without Statins, Asthma Treatments
FDA Aims To “NSURE” Clarity About New Paradigm For OTC Switches
Prilosec 1 “approvable”


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts